• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconWeight Loss

Weight Loss

Page 2 of 6
Doctor listening with a stethoscope to the heart of an overweight Asian woman
LifePatients call out fat-shaming doctors for hurting their health: ‘I always go in with my guard up’
By Ani FreedmanFebruary 11, 2025
7 micro habits one woman in early menopause used to lose 50 pounds
Life7 micro habits one woman in early menopause used to lose 50 pounds
By Ani FreedmanFebruary 7, 2025
Two girls, drinking pints of lager, dancing and smiling
Health6 ways your brain and body benefit when you stop drinking alcohol
By Kristine GillFebruary 6, 2025
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
HealthAs growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
By Ryan HoggFebruary 5, 2025
Novo Nordisk advertising logo on facade building, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
HealthInvestors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
By Ryan HoggFebruary 4, 2025
A person stands on a scale.
HealthHims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
By Lindsey LeakeFebruary 3, 2025
Ozempic and Wegovy medications side by side
HealthOzempic and Wegovy surge to national approval with most U.S. adults considering it ‘a good thing’ to treat obesity
By The Associated Press, Kenya Hunter and Linley SandersJanuary 31, 2025
The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
HealthOnline searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next
By Lindsey LeakeJanuary 29, 2025
A person, with only the midsection visible, injects Wegovy under the skin of their stomach.
FinanceNovo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
By Greg McKennaJanuary 24, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
HealthHate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says
By Lindsey LeakeJanuary 21, 2025
Portrait of Crunch Fitness CEO Jim Rowley seated at Fortune's video studio.
SuccessThe CEO of Crunch Fitness doesn’t think there’s such a thing as work-life balance: ‘That’s for somebody who’s not fully committed’
By Jane Thier and Fortune EditorsJanuary 16, 2025
Radical new proposal from 58 medical experts would decenter BMI from obesity diagnosis
HealthRadical new proposal from 58 medical experts would decenter BMI from obesity diagnosis
By Ani FreedmanJanuary 14, 2025
Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
HealthElon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
By Alexa MikhailDecember 27, 2024
Keto vs. paleo diet: which one is better? Experts weigh in
LifeKeto vs. paleo diet: which one is better? Experts weigh in
By Ani FreedmanDecember 20, 2024
Merck snags Chinese obesity drug in nearly $2 billion deal
TechMerck snags Chinese obesity drug in nearly $2 billion deal
By Robert Langreth and BloombergDecember 18, 2024
1
  • 1
  • 2
  • 3
  • 4
  • 5
6
Most Popular
Economy
The U.S. government is spending $88 billion a month in interest on national debt—equal to spending on defense and education combinedplaceholder alt text
By Fortune EditorsApril 9, 2026
Energy
2 years ago, Saudi Arabia quietly canceled the ‘petrodollar’ deal with America that wired the world economy for 50 years. Then war broke out in Iranplaceholder alt text
By Fortune EditorsApril 7, 2026
Economy
The U.S. had a national debt ‘home run’ in its grasp, says Jamie Dimon. But the government did nothing, and now its best option is crisis managementplaceholder alt text
By Fortune EditorsApril 8, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.